Breast cancer is the leading cause of death among women in China and worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment for metastatic breast cancer. Antibody-drug conjugates (ADCs) are a new type of anticancer drug consisting of antibodies, linkers, and cytotoxic agents [1]. … Read more
Introduction The design of clinically successful ADCs depends not only on the potency of the payload and its attachment points, the stability of the linker, and effective drug release, but also on the choice of antibodies and bioconjugation technology. Over the past decade, all FDA-approved ADCs have existed in the form of heterogeneous mixtures of … Read more
ADCs have become a promising class of anti-tumor drugs, with over a dozen ADCs approved for treating various types of cancer patients. Traditional ADCs utilize the amino groups of antibody lysines or the thiol groups obtained from the reduction of inter-chain disulfide bonds in cysteines for coupling. However, their uniformity is poor, and stability is … Read more
Antibody-drug conjugates (ADC) mainly consist of three “modules”: an antibody (generally a monoclonal antibody), a linker, and a cytotoxic drug (Payload). In recent years, ADC drugs have stood out among biopharmaceuticals due to their combination of the potent killing effect of chemotherapy drugs and the precise targeting of antibody drugs, earning them the title of … Read more
The ADC field has gradually been pushed to market since 2000, and in recent years has surged in cancer treatment, leading to rapid development and fierce competition in this sector. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology applications. Although the number of related ADCs is very small and most are … Read more
Source: YaoDu Author: Cheng Chuan Yuan Hang Editor: Wan Zi 1 Introduction Antibody-Drug Conjugates (ADCs) are a novel class of highly effective biopharmaceuticals that link antibodies (Antibody) to biologically active small-molecule cytotoxic payloads (Payload) via linkers (Linker). ADCs aim to enhance the therapeutic index (TI) of chemotherapeutic agents by more selectively delivering cytotoxic drugs to … Read more
Introduction In addition to the need for ADCs to target antigens that are overexpressed in tumors, another important factor is the efficiency of endocytosis, which is necessary for the release of the drug’s active payload. In fact, the efficacy of ADCs depends on the efficiency of targeted-mediated internalization to deliver effective payloads within tumor cells. … Read more
Let’s take a moment to focus on the recent hot topic of Antibody–Drug Conjugates and systematically learn about the review published in Cancers: Antibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, aside from endocrine therapy and targeted drugs, the common treatment method for metastatic breast cancer (BC) is chemotherapy. However, the lack of … Read more
Click the above Xingzhou Drug ▲ Follow This year, CED released the draft for comments on the “Technical Guidelines for Non-Clinical Research of Antibody-Drug Conjugates (ADC)”, which provides assistance for companies conducting non-clinical research on ADCs.It provides guidance on non-clinical studies such as “pharmacology, safety pharmacology, pharmacokinetics, and toxicology”. (1) PharmacologyIn the early development of … Read more
▲May 2022, Improved New Drug Trends and Technology Conference·Limited TimeFree Registration Ongoing Note:This article does not constitute any investment opinions or advice, subject to official/company announcements;This article is only for the introduction of medical health-related drugs, not a recommendation for treatment plans (if involved), and does not represent the platform’s position.Any article reproduction requires authorization. … Read more